Skip to main content
SpringerLink
Log in

Anabolic agents: what is beyond osteoporosis?

  • Review
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Osteoporosis is a common skeletal disorder characterized by low bone mass, which leads to reduced bone strength and an increased risk of fractures. Anabolic agents have been shown to improve bone mass and decrease fracture risk in osteoporosis patients by directly stimulating osteoblasts to produce new bone. Currently, two anabolic agents are available in the USA: recombinantly produced teriparatide (TPTD), which is the fully active (1–34) amino active sequence of human parathyroid hormone (PTH), and abaloparatide (APTD), a synthetic analog of parathyroid hormone-related peptide (PTHrP). At present, both agents are approved only for treatment of patients with osteoporosis at high risk of fracture. Nonetheless, their anabolic properties have led to off-label application in additional settings which include spine fusion, osteonecrosis of the jaw, arthroplasty, and fracture healing. In this article, we summarize available scientific literature regarding the efficacy, effectiveness, and safety of TPTD in these off-label settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ensrud KE, Crandall CJ (2017) Osteoporosis. Ann Intern Med 167:ITC17–ITC32

    Article  PubMed  Google Scholar 

  2. Sozen T, Ozisik L, Basaran NC (2017) An overview and management of osteoporosis. Eur J Rheumatol 4:46–56

    Article  PubMed  Google Scholar 

  3. Chew CK, Clarke BL (2017) Abaloparatide: recombinant human PTHrP (1-34) anabolic therapy for osteoporosis. Maturitas 97:53–60

    Article  CAS  PubMed  Google Scholar 

  4. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039

    Article  CAS  PubMed  Google Scholar 

  5. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916

    Article  CAS  PubMed  Google Scholar 

  6. Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ (2016) Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157:141–149

    Article  CAS  PubMed  Google Scholar 

  7. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CAF, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, for the ACTIVE Study Investigators (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316:722–733

    Article  CAS  PubMed  Google Scholar 

  8. Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. In: Lancet, vol 390, pp 1585–1594

    Google Scholar 

  9. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med

  10. Chaudhary N, Lee JS, Wu JY, Tharin S (2017) Evidence for use of teriparatide in spinal fusion surgery in osteoporotic patients. World Neurosurg 100:551–556

    Article  PubMed  Google Scholar 

  11. Yishake M, Yasen M, Jiang L, Liu W, Xing R, Chen Q, Lin H, Dong J (2017) Effects of combined teriparatide and zoledronic acid on posterior lumbar vertebral fusion in an aged ovariectomized rat model of osteopenia. J Orthop Res

  12. Sugiura T, Kashii M, Matsuo Y, Morimoto T, Honda H, Kaito T, Iwasaki M, Yoshikawa H (2015) Intermittent administration of teriparatide enhances graft bone healing and accelerates spinal fusion in rats with glucocorticoid-induced osteoporosis. Spine J 15:298–306

    Article  PubMed  Google Scholar 

  13. Lina IA, Puvanesarajah V, Liauw JA et al (2014) Quantitative study of parathyroid hormone (1-34) and bone morphogenetic protein-2 on spinal fusion outcomes in a rabbit model of lumbar dorsolateral intertransverse process arthrodesis. Spine (Phila Pa 1976) 39:347–355

    Article  Google Scholar 

  14. Qiu Z, Wei L, Liu J, Sochacki KR, Liu X, Bishop C, Ebraheim M, Yang H (2013) Effect of intermittent PTH (1-34) on posterolateral spinal fusion with iliac crest bone graft in an ovariectomized rat model. Osteoporos Int 24:2693–2700

    Article  CAS  PubMed  Google Scholar 

  15. Ming N, Cheng JT, Rui YF, Chan KM, Kuhstoss S, Ma YL, Sato M, Wang Y, Li G (2012) Dose-dependent enhancement of spinal fusion in rats with teriparatide (PTH[1–34]). Spine (Phila Pa 1976) 37:1275–1282

    Article  Google Scholar 

  16. Lehman RA Jr, Dmitriev AE, Cardoso MJ, Helgeson MD, Christensen CL, Raymond JW, Eckel TT, Riew KD (2010) Effect of teriparatide [rhPTH(1,34)] and calcitonin on intertransverse process fusion in a rabbit model. Spine (Phila Pa 1976) 35:146–152

    Article  Google Scholar 

  17. O'Loughlin PF, Cunningham ME, Bukata SV, Tomin E, Poynton AR, Doty SB, Sama AA, Lane JM (2009) Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model. Spine (Phila Pa 1976) 34:121–130

    Article  Google Scholar 

  18. Abe Y, Takahata M, Ito M, Irie K, Abumi K, Minami A (2007) Enhancement of graft bone healing by intermittent administration of human parathyroid hormone (1-34) in a rat spinal arthrodesis model. Bone 41:775–785

    Article  CAS  PubMed  Google Scholar 

  19. Lawrence JP, Ennis F, White AP, Magit D, Polzhofer G, Drespe I, Troiano NW, Grauer JN (2006) Effect of daily parathyroid hormone (1-34) on lumbar fusion in a rat model. Spine J 6:385–390

    Article  PubMed  Google Scholar 

  20. Keskinruzgar A, Bozdag Z, Aras MH, Demir T, Yolcu U, Cetiner S (2016) Histopathological effects of teriparatide in medication-related osteonecrosis of the jaw: an animal study. J Oral Maxillofac Surg 74:68–78

    Article  PubMed  Google Scholar 

  21. Dayisoylu EH, Senel FC, Ungor C, Tosun E, Cankaya M, Ersoz S, Taskesen F (2013) The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study. Int J Oral Maxillofac Surg 42:1475–1480

    Article  CAS  PubMed  Google Scholar 

  22. Daugaard H, Elmengaard B, Andreassen T, Bechtold J, Lamberg A, Soballe K (2011) Parathyroid hormone treatment increases fixation of orthopedic implants with gap healing: a biomechanical and histomorphometric canine study of porous coated titanium alloy implants in cancellous bone. Calcif Tissue Int 88:294–303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Li YF, Li XD, Bao CY, Chen QM, Zhang H, Hu J (2013) Promotion of peri-implant bone healing by systemically administered parathyroid hormone (1-34) and zoledronic acid adsorbed onto the implant surface. Osteoporos Int 24:1063–1071

    Article  CAS  PubMed  Google Scholar 

  24. Nakajima A, Shimoji N, Shiomi K, Shimizu S, Moriya H, Einhorn TA, Yamazaki M (2002) Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 17:2038–2047

    Article  CAS  PubMed  Google Scholar 

  25. Andreassen TT, Ejersted C, Oxlund H (1999) Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 14:960–968

    Article  CAS  PubMed  Google Scholar 

  26. Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA (2005) Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 87:731–741

    PubMed  Google Scholar 

  27. Manabe T, Mori S, Mashiba T, Kaji Y, Iwata K, Komatsubara S, Seki A, Sun YX, Yamamoto T (2007) Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone 40:1475–1482

    Article  CAS  PubMed  Google Scholar 

  28. Tagil M, McDonald MM, Morse A, Peacock L, Mikulec K, Amanat N, Godfrey C, Little DG (2010) Intermittent PTH(1-34) does not increase union rates in open rat femoral fractures and exhibits attenuated anabolic effects compared to closed fractures. Bone 46:852–859

    Article  PubMed  Google Scholar 

  29. Morgan EF, Mason ZD, Bishop G, Davis AD, Wigner NA, Gerstenfeld LC, Einhorn TA (2008) Combined effects of recombinant human BMP-7 (rhBMP-7) and parathyroid hormone (1-34) in metaphyseal bone healing. Bone 43:1031–1038

    Article  CAS  PubMed  Google Scholar 

  30. Cohn Yakubovich D, Sheyn D, Bez M, Schary Y, Yalon E, Sirhan A, Amira M, Yaya A, de Mel S, da X, Ben-David S, Tawackoli W, Ley EJ, Gazit D, Gazit Z, Pelled G (2017) Systemic administration of mesenchymal stem cells combined with parathyroid hormone therapy synergistically regenerates multiple rib fractures. Stem Cell Res Ther 8:51

    Article  PubMed  PubMed Central  Google Scholar 

  31. Li YF, Zhou CC, Li JH, Luo E, Zhu SS, Feng G, Hu J (2012) The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos Int 23:1463–1474

    Article  CAS  PubMed  Google Scholar 

  32. Komrakova M, Stuermer EK, Werner C, Wicke M, Kolios L, Sehmisch S, Tezval M, Daub F, Martens T, Witzenhausen P, Dullin C, Stuermer KM (2010) Effect of human parathyroid hormone hPTH (1-34) applied at different regimes on fracture healing and muscle in ovariectomized and healthy rats. Bone 47:480–492

    Article  CAS  PubMed  Google Scholar 

  33. Lin EA, Liu CJ, Monroy A, Khurana S, Egol KA (2012) Prevention of atrophic nonunion by the systemic administration of parathyroid hormone (PTH 1-34) in an experimental animal model. J Orthop Trauma 26:719–723

    Article  PubMed  Google Scholar 

  34. Sloan AV, Martin JR, Li S, Li J (2010) Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair. Bone 47:235–240

    Article  CAS  PubMed  Google Scholar 

  35. Ohtori S, Orita S, Yamauchi K, Eguchi Y, Aoki Y, Nakamura J, Suzuki M, Kubota G, Inage K, Shiga Y, Abe K, Fujimoto K, Kanamoto H, Inoue M, Kinoshita H, Furuya T, Koda M (2017) Does discontinuing teriparatide treatment and replacing it with bisphosphonate maintain the volume of the bone fusion mass after lumbar posterolateral fusion in women with postmenopausal osteoporosis? Asian Spine J 11:272–277

    Article  PubMed  PubMed Central  Google Scholar 

  36. Kaliya-Perumal AK, Lu ML, Luo CA, Tsai TT, Lai PL, Chen LH, Chen WJ, Niu CC (2017) Retrospective radiological outcome analysis following teriparatide use in elderly patients undergoing multilevel instrumented lumbar fusion surgery. Medicine (Baltimore) 96:e5996

    Article  CAS  Google Scholar 

  37. Ohtori S, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kuniyoshi K, Aoki Y, Nakamura J, Miyagi M, Suzuki M, Kubota G, Inage K, Sainoh T, Sato J, Shiga Y, Abe K, Fujimoto K, Kanamoto H, Inoue G, Takahashi K (2015) More than 6 months of teriparatide treatment was more effective for bone union than shorter treatment following lumbar posterolateral fusion surgery. Asian Spine J 9:573–580

    Article  PubMed  PubMed Central  Google Scholar 

  38. Inoue G, Ueno M, Nakazawa T, Imura T, Saito W, Uchida K, Ohtori S, Toyone T, Takahira N, Takaso M (2014) Teriparatide increases the insertional torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis. J Neurosurg Spine 21:425–431

    Article  PubMed  Google Scholar 

  39. Cho PG, Ji GY, Shin DA, Ha Y, Yoon DH, Kim KN (2017) An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data. Eur Spine J 26:691–697

    Article  PubMed  Google Scholar 

  40. Ebata S, Takahashi J, Hasegawa T, Mukaiyama K, Isogai Y, Ohba T, Shibata Y, Ojima T, Yamagata Z, Matsuyama Y, Haro H (2017) Role of weekly teriparatide administration in osseous union enhancement within six months after posterior or transforaminal lumbar interbody fusion for osteoporosis-associated lumbar degenerative disorders: a multicenter, prospective randomized study. J Bone Joint Surg Am 99:365–372

    Article  PubMed  Google Scholar 

  41. Seki S, Hirano N, Kawaguchi Y, Nakano M, Yasuda T, Suzuki K, Watanabe K, Makino H, Kanamori M, Kimura T (2017) Teriparatide versus low-dose bisphosphonates before and after surgery for adult spinal deformity in female Japanese patients with osteoporosis. Eur Spine J 26:2121–2127

    Article  PubMed  Google Scholar 

  42. Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Nakamura J, Ishikawa T, Miyagi M, Kamoda H, Suzuki M, Kubota G, Sakuma Y, Oikawa Y, Inage K, Sainoh T, Takaso M, Toyone T, Takahashi K (2013) Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine (Phila Pa 1976) 38:E487–E492

    Article  Google Scholar 

  43. Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Nakamura J, Ishikawa T, Miyagi M, Kamoda H, Suzuki M, Kubota G, Sakuma Y, Oikawa Y, Inage K, Sainoh T, Takaso M, Ozawa T, Takahashi K, Toyone T (2012) Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study. Spine (Phila Pa 1976) 37:E1464–E1468

    Article  Google Scholar 

  44. Jung J, Yoo HY, Kim GT, Lee JW, Lee YA, Kim DY, Kwon YD (2017) Short-term teriparatide and recombinant human bone morphogenetic protein-2 for regenerative approach to medication-related osteonecrosis of the jaw: a preliminary study. J Bone Miner Res

  45. Kim KM, Park W, Oh SY, Kim HJ, Nam W, Lim SK, Rhee Y, Cha IH (2014) Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw. Osteoporos Int 25:1625–1632

    Article  CAS  PubMed  Google Scholar 

  46. Kaneko T, Otani T, Kono N, Mochizuki Y, Mori T, Nango N, Ikegami H, Musha Y (2016) Weekly injection of teriparatide for bone ingrowth after cementless total knee arthroplasty. J Orthop Surg (Hong Kong) 24:16–21

    Article  CAS  Google Scholar 

  47. Huang TW, Huang KC, Lin SJ, Chuang PY, Shih HN, Lee MS, Hsu RW, Shen WJ (2016) Effects of teriparatide on cementless bipolar hemiarthroplasty in patients with osteoporotic femoral neck fractures. BMC Musculoskelet Disord 17:300

    Article  PubMed  PubMed Central  Google Scholar 

  48. Kobayashi N, Inaba Y, Uchiyama M, Ike H, Kubota S, Saito T (2016) Teriparatide versus alendronate for the preservation of bone mineral density after Total hip arthroplasty—a randomized controlled trial. J Arthroplast 31:333–338

    Article  Google Scholar 

  49. Ledin H, Good L, Johansson T, Aspenberg P (2017) No effect of teriparatide on migration in total knee replacement. Acta Orthop 88:259–262

    Article  PubMed  PubMed Central  Google Scholar 

  50. Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, García-Hernández PA, Recknor CP, Einhorn TA, Dalsky GP, Mitlak BH, Fierlinger A, Lakshmanan MC (2010) Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 25:404–414

    Article  CAS  PubMed  Google Scholar 

  51. Aspenberg P, Johansson T (2010) Teriparatide improves early callus formation in distal radial fractures. Acta Orthop 81:234–236

    Article  PubMed  PubMed Central  Google Scholar 

  52. Peichl P, Holzer LA, Maier R, Holzer G (2011) Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 93:1583–1587

    Article  PubMed  Google Scholar 

  53. Miller PD, McCarthy EF (2015) Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. Semin Arthritis Rheum 44:477–482

    Article  CAS  PubMed  Google Scholar 

  54. Kim JT, Jeong HJ, Lee SJ, Kim HJ, Yoo JJ (2016) Adjuvant teriparatide therapy for surgical treatment of femoral fractures; does it work? Hip Pelvis 28:148–156

    Article  PubMed  PubMed Central  Google Scholar 

  55. Miyakoshi N, Aizawa T, Sasaki S, Ando S, Maekawa S, Aonuma H, Tsuchie H, Sasaki H, Kasukawa Y, Shimada Y (2015) Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. J Bone Miner Metab 33:553–559

    Article  CAS  PubMed  Google Scholar 

  56. Watts NB, Aggers D, McCarthy EF, Savage T, Martinez S, Patterson R, Carrithers E, Miller PD (2017) Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. J Bone Miner Res 32:1027–1033

    Article  CAS  PubMed  Google Scholar 

  57. Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E (2013) Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 52:360–365

    Article  CAS  PubMed  Google Scholar 

  58. Lee YK, Ha YC, Koo KH (2012) Teriparatide, a nonsurgical solution for femoral nonunion? A report of three cases. Osteoporos Int 23:2897–2900

    Article  PubMed  Google Scholar 

  59. Xiaofeng L, Daxia X, Yunzhen C (2017) Teriparatide as a nonoperative treatment for tibial and femoral fracture nonunion: a case report. Medicine (Baltimore) 96:e6571

    Article  Google Scholar 

  60. Emanuele C, Leonardo P, Gianfilippo C, Matteo A, Doria C (2017) Peri-prosthetic humeral non-union: where biology meets bio-mechanic. A case report. Int J Surg Case Rep 39:102–105

    Article  PubMed  PubMed Central  Google Scholar 

  61. Bednar DA (2013) Teriparatide treatment of a glucocorticoid-associated resorbing nonunion of a type III odontoid process fracture: a case report. J Spinal Disord Tech 26:E319–E322

    Article  PubMed  Google Scholar 

  62. Raghavan P, Christofides E (2012) Role of teriparatide in accelerating metatarsal stress fracture healing: a case series and review of literature. Clin Med Insights Endocrinol Diabetes 5:39–45

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Whyte MP, Mumm S, Deal C (2007) Adult hypophosphatasia treated with teriparatide. J Clin Endocrinol Metab 92:1203–1208

    Article  CAS  PubMed  Google Scholar 

  64. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL (2003) Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539–543

    Article  CAS  PubMed  Google Scholar 

  65. Schnell R, Graeff C, Krebs A, Oertel H, Gluer CC (2010) Changes in cross-sectional area of spinal canal and vertebral body under 2 years of teriparatide treatment: results from the EUROFORS study. Calcif Tissue Int 87:130–136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Cheung A, Seeman E (2010) Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 363:2473–2474

    Article  CAS  PubMed  Google Scholar 

  67. El-Rabbany M, Sgro A, Lam DK, Shah PS, Azarpazhooh A (2017) Effectiveness of treatments for medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. J Am Dent Assoc 148(584–594):e582

    Google Scholar 

  68. Yoshiga D, Yamashita Y, Nakamichi I, Tanaka T, Yamauchi K, Yamamoto N, Nogami S, Kaneuji T, Mitsugi S, Sakurai T, Kiyomiya H, Tominaga K, Morimoto Y, Takahashi T (2013) Weekly teriparatide injections successfully treated advanced bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int 24:2365–2369

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Bashutski JD, Eber RM, Kinney JS, Benavides E, Maitra S, Braun TM, Giannobile WV, McCauley LK (2010) Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 363:2396–2405

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, el Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, on behalf of the International Task Force on Osteonecrosis of the Jaw (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3–23

    Article  PubMed  Google Scholar 

  71. Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA (2010) Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 21:1041–1045

    Article  CAS  PubMed  Google Scholar 

  72. Oteo-Alvaro A, Matas JA, Alonso-Farto JC (2011) Teriparatide (rh [1-34] PTH) improved osteointegration of a hemiarthroplasty with signs of aseptic loosening. Orthopedics 34:e574–e577

    PubMed  Google Scholar 

  73. Zati A, Sarti D, Malaguti MC, Pratelli L (2011) Teriparatide in the treatment of a loose hip prosthesis. J Rheumatol 38:778–780

    Article  PubMed  Google Scholar 

  74. Suzuki T, Ryu K, Kojima K, Saito S, Nagaoka H, Tokuhashi Y (2017) Teriparatide treatment improved loosening of cementless total knee arthroplasty: a case report. J Orthop Case Rep 7:32–35

    PubMed  PubMed Central  Google Scholar 

  75. Einhorn TA, Gerstenfeld LC (2015) Fracture healing: mechanisms and interventions. Nat Rev Rheumatol 11:45–54

    Article  PubMed  Google Scholar 

  76. Kakar S, Einhorn TA, Vora S, Miara LJ, Hon G, Wigner NA, Toben D, Jacobsen KA, al-Sebaei MO, Song M, Trackman PC, Morgan EF, Gerstenfeld LC, Barnes GL (2007) Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res 22:1903–1912

    Article  CAS  PubMed  Google Scholar 

  77. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MCH, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23

    Article  PubMed  Google Scholar 

  78. Gomberg SJ, Wustrack RL, Napoli N, Arnaud CD, Black DM (2011) Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 96:1627–1632

    Article  CAS  PubMed  Google Scholar 

  79. Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F (2011) Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab 96:2675–2680

    Article  CAS  PubMed  Google Scholar 

  80. Tjhia CK, Odvina CV, Rao DS, Stover SM, Wang X, Fyhrie DP (2011) Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. Bone 49:1279–1289

    Article  PubMed  PubMed Central  Google Scholar 

  81. Seeman E, Delmas PD (2006) Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–2261

    Article  CAS  PubMed  Google Scholar 

  82. Moreira CA, Bilezikian JP (2017) Stress fractures: concepts and therapeutics. J Clin Endocrinol Metab 102:525–534

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopedic Surgery, Hospital for Special Surgery, Weill Cornell Medical College, 535 East 70th Street, New York, NY, 10021, USA

    Y. Liu, A. E. Levack, E. Marty, O. Or, B. P. Samuels, M. Redko & J. M. Lane

  2. Department of Orthopedic Surgery, Hadassah Medical Center, 91120, Jerusalem, Israel

    O. Or

Authors
  1. Y. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. E. Levack
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Marty
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. O. Or
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. P. Samuels
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Redko
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. M. Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. M. Lane.

Ethics declarations

Conflict of interest

Dr. Joseph Lane is a co-principal investigator for a trial of teriparatide and pelvic fracture (NIH: 1U01AR069869-01). Ashley E. Levack is supported by NIH T32 AR007281. Yi Liu, Eric Marty, Omer Or, Blossom P. Samuels, and Mariya Redko declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Y., Levack, A.E., Marty, E. et al. Anabolic agents: what is beyond osteoporosis?. Osteoporos Int 29, 1009–1022 (2018). https://doi.org/10.1007/s00198-018-4507-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-018-4507-8

Keywords

Search

Navigation